119 related articles for article (PubMed ID: 36867734)
1. SEPT9 Expression in Hepatic Nodules: An Immunohistochemical Study of Hepatocellular Neoplasm and Metastasis.
Kmeid M; Park YN; Chung T; Pacheco RR; Arslan ME; Lee H
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):278-287. PubMed ID: 36867734
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
[TBL] [Abstract][Full Text] [Related]
3. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
[TBL] [Abstract][Full Text] [Related]
4.
Li B; Huang H; Huang R; Zhang W; Zhou G; Wu Z; Lv C; Han X; Jiang L; Li Y; Li B; Zhang Z
Dis Markers; 2020; 2020():6289063. PubMed ID: 33178361
[TBL] [Abstract][Full Text] [Related]
5. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.
Huang F; Yang G; Jiang H; Chen X; Yang Y; Yu Q; Pan B; Wang B; Guo W; Yang W; Zhang C
Technol Cancer Res Treat; 2022; 21():15330338221144510. PubMed ID: 36573042
[No Abstract] [Full Text] [Related]
6. Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma.
Bannaga AS; Alvarez R; Zhou L; Petchey M; Noufaily A; Hitchins MP; Arasaradnam RP
HPB (Oxford); 2021 Oct; 23(10):1595-1606. PubMed ID: 33931320
[TBL] [Abstract][Full Text] [Related]
7. Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring.
Wong IH; Lau WY; Leung T; Johnson PJ
Cancer Lett; 2000 Aug; 156(2):141-9. PubMed ID: 10880763
[TBL] [Abstract][Full Text] [Related]
8. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
[TBL] [Abstract][Full Text] [Related]
9. PSMA Immunohistochemistry in Hepatic Neoplasms: A Promising Diagnostic Marker With Potential Theranostic Applications.
Kmeid M; Park YN; Chung T; Lukose G; Sullivan L; Brar R; Lee H
Am J Surg Pathol; 2022 Dec; 46(12):1688-1699. PubMed ID: 36190927
[TBL] [Abstract][Full Text] [Related]
10. Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.
Zheng K; Dai L; Zhao Y; Li L; Li W; Zhang X; Su Q; Wu R; Jiang Y; Chen Y; Ran J
BMC Gastroenterol; 2023 Jul; 23(1):260. PubMed ID: 37525116
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
13. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I; Suehiro Y; Yamauchi Y; Hoshida T; Tanabe N; Oono T; Kawamoto D; Nishimura T; Matsumoto T; Ishikawa T; Shimokawa M; Tamori A; Kawada N; Tamai Y; Iwasa M; Nakagawa H; Nagano H; Takami T; Yamasaki T
Hepatol Int; 2023 Oct; 17(5):1289-1299. PubMed ID: 37186217
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
16. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
18. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
19. Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.
Chen SP; Zhang LS; Fu BS; Zeng XC; Yi HM; Jiang N
Medicine (Baltimore); 2015 Jan; 94(4):e423. PubMed ID: 25634174
[TBL] [Abstract][Full Text] [Related]
20. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.
Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
